Therapy For Alopecia Research Articles

Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation

The etiology of alopecia is so complex that current therapies with single-mechanism and attendant side-effects during long-term usage, are insufficient for treatment. Panax notoginseng saponins (PNS) is supposed to treat alopecia with multiple mechanisms, but difficult to penetrate skin efficiently due to water-solubility. Here, we designed water-in-oil microemulsion (PNS ME) using jojoba oil, fractioned coconut oil, RH 40 + Span 80 and cosurfactant D-panthenol, to help PNS penetrating the skin. Particularly, D-panthenol not only enlarges the microemulsion area, reduces the usage amounts of surfactants thus relieves skin irritation, but stimulates the migration of dermal papilla cells (DPCs), displaying cooperative effects on anti-alopecia. PNS ME penetrates through sebum-rich corneum via high-affinity lipid fusion, targets to hair follicles (HFs), where it resides in skin for sustained drug release, accelerates angiogenesis to build well-nourished environment for HFs, and facilitates the proliferation and migration of DPCs in vitro. PNS ME markedly improved hair density, skin pigmentation, new hair weight, skin thickness, and collagen generation of telogen effluvium mice. Moreover, PNS also took outstanding curative effects on androgenetic alopecia mice. Upon further exploration, PNS ME caused dramatic upregulations of β-catenin, VEGF and Ki67, suggesting it might function by triggering Wnt/β-catenin pathway, accelerating vessels formation, and activating the hair follicle stem cells. Notably, PNS ME indicated longer-term safety than minoxidil tincture. Together, PNS ME provides a comprehensive strategy for alopecia, especially it avoids defects by high-proportioned surfactants in traditional microemulsion, exhibiting milder and safer, which shows bright prospect of applying microemulsion in hair growth promotion.

A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy.

While large-scale artificial intelligence (AI) models for protein structure prediction and design are advancing rapidly, the translation of deep learning models for practical macromolecular drug development remains limited. This investigation aims to bridge this gap by combining cutting-edge methodologies to create a novel peptide-based PROTAC drug development paradigm. Using ProteinMPNN and RFdiffusion, we identified binding peptides for androgen receptor (AR) and Von Hippel-Lindau (VHL), followed by computational modeling with Alphafold2-multimer and ZDOCK to predict spatial interrelationships. Experimental validation confirmed the designed peptide's binding ability to AR and VHL. Transdermal microneedle patching technology was seamlessly integrated for the peptide PROTAC drug delivery in androgenic alopecia treatment. In summary, our approach provides a generic method for generating peptide PROTACs and offers a practical application for designing potential therapeutic drugs for androgenetic alopecia. This showcases the potential of interdisciplinary approaches in advancing drug development and personalized medicine.

Can Plant Extracts Help Prevent Hair Loss or Promote Hair Growth? A Review Comparing Their Therapeutic Efficacies, Phytochemical Components, and Modulatory Targets

This narrative review aims to examine the therapeutic potential and mechanism of action of plant extracts in preventing and treating alopecia (baldness). We searched and selected research papers on plant extracts related to hair loss, hair growth, or hair regrowth, and comprehensively compared the therapeutic efficacies, phytochemical components, and modulatory targets of plant extracts. These studies showed that various plant extracts increased the survival and proliferation of dermal papilla cells in vitro, enhanced cell proliferation and hair growth in hair follicles ex vivo, and promoted hair growth or regrowth in animal models in vivo. The hair growth-promoting efficacy of several plant extracts was verified in clinical trials. Some phenolic compounds, terpenes and terpenoids, sulfur-containing compounds, and fatty acids were identified as active compounds contained in plant extracts. The pharmacological effects of plant extracts and their active compounds were associated with the promotion of cell survival, cell proliferation, or cell cycle progression, and the upregulation of several growth factors, such as IGF-1, VEGF, HGF, and KGF (FGF-7), leading to the induction and extension of the anagen phase in the hair cycle. Those effects were also associated with the alleviation of oxidative stress, inflammatory response, cellular senescence, or apoptosis, and the downregulation of male hormones and their receptors, preventing the entry into the telogen phase in the hair cycle. Several active plant extracts and phytochemicals stimulated the signaling pathways mediated by protein kinase B (PKB, also called AKT), extracellular signal-regulated kinases (ERK), Wingless and Int-1 (WNT), or sonic hedgehog (SHH), while suppressing other cell signaling pathways mediated by transforming growth factor (TGF)-β or bone morphogenetic protein (BMP). Thus, well-selected plant extracts and their active compounds can have beneficial effects on hair health. It is proposed that the discovery of phytochemicals targeting the aforementioned cellular events and cell signaling pathways will facilitate the development of new targeted therapies for alopecia.

Vibration assisted analgesia during intralesional corticosteroid therapy for alopecia

Vibration assisted analgesia during intralesional corticosteroid therapy for alopecia

Patient perspectives on topical minoxidil for hair loss: a survey-based study from the University of Michigan Alopecia Clinic.

Topical minoxidil is a widely used therapy for alopecia. Its availability over the counter in the United States makes it easily accessible. Various factors impact whether an individual decides to pursue treatment and/or continue long-term use. Our study aimed to investigate patient awareness, opinions, and hesitations regarding topical minoxidil use for hair loss treatment. The study also aimed to identify information sources influencing these viewpoints. A survey was administered to new patients seeking evaluation for alopecia aged 18 and above at the University of Michigan Alopecia Clinic. Data collection occurred between August 2022 and August 2023. Demographics, patient-reported hair loss diagnosis, history of minoxidil use, opinions on minoxidil, influential information sources, and concerns about minoxidil were collected. A total of 47 surveys were completed, primarily by females (78.7%) ages 18-40years (44.7%). Respondents were aware of minoxidil (97.9%), with 63.8% reporting they had heard of minoxidil, but had not used it. Medical professionals were the most influential information source (34%), followed by close contacts (17%), internet searches (10.6%), and television (10.6%). Overall, positive opinions on minoxidil were expressed by 51.1%, negative opinions by 31.9%, and neutral opinions by 17%. Most common concerns included the need for continuous use (46.8%), required regular application (31.9%), skepticism about hair regrowth (29.8%), and expense (25.5%). Addressing personalized concerns and tailoring communication based on hair loss type and information sources may lead to more informed decisions and improved adherence. Gauging the opinions of this population provides valuable insights, aiding dermatologists in patient education and counseling strategies.

The Effect of Topical Gel Secretome Hypoxic Mesenchymal Stem Cells (SH-MSCs) on IL-6 and TGF- β Gene Expression (Experimental Study in Male Wistar Alopecia-Like Rat Models Induced by Fluconazole)

Alopecia induced by the accumulation of reactive oxygen species (ROS) stimulates changes in the immune and neuroendocrine systems. Hair follicles have dermal papillary cells (DPCs) that bind to corticotropin-releasing factor (CRF) receptors. Research shows that transforming growth factor (TGF-β) is one of the expressions that can be an indication of the influence of CRF. The effect of CRF itself is to cause hair loss. The purpose of this study was to determine the Secretome of Hypoxia Mesenchymal Stem Cells (SH-MSCs) against IL-6 expression and TGF-β expression. This study used experimentally in vivo with the Post Test Only Control Group Design method. The subjects of this study were male rats of Wistar strain which were divided into 4 treatments consisting of 1 healthy group, 1 negative control group, 1 treatment group with SH-MSCs dose 10% in a dose of 200 mg/rat/day gel, and 1 more treatment group with SH-MSCs dose 20% in a dose of 200 mg/rat/day. On the 21st day, IL-6 expression and TGF-β expression were examined. Data were analyzed using the One-Way ANOVA Test and the Kruskall-Wallis Test to determine the effect of each group. The One-Way ANOVA test showed the results of IL-6 expression (p = 0.000) showed a significant difference (p < 0.05) and the Kruskall-Wallis test of TGF-β expression (p = 0.000) with SH-MSCs dose 200 was a significant difference (p < 0.05). The administration of 10% and 20% doses of SH-MSCs in 200 mg gel may decrease IL-6 expression. Dosed SH-MSCs 20%increased TGF-β expression in alopecia-like rats. The development of the use of SH-MSCs is expected to be an alternative to alopecia therapy that is more beneficial and safe for the body.

Formulation and Evaluation of Herbal Cream for the Management of Androgenetic Alopecia

The current study aimed to develop a herbal hair cream formulation including plant extracts traditionally used for hair growth, and further research was conducted to understand the hair growth capability better using the 5 alpha reductase inhibitory model. 5 alpha reductases, an enzyme confined to the nuclear membrane, converts testosterone into dihydrotestosterone. The 5 alpha-reductase and its metabolite dihydrotestosterone influence various human disorders, including male pattern baldness, benign prostatic hyperplasia (BPH), and prostate cancer. Finasteride and alfatradiol are examples of synthetic medications; however, because of their negative impacts, researchers are currently focused on creating safer 5α-reductase inhibitors from plants. The hair cream formulation contained 0.5% extracts of Hibiscus rosa sinensis flower, Eclipta alba whole plant, and Solanum nigrum plant berries in a ratio of 1:1:1. Plant extracts used in the formulation were characterized by chemical biomarkers. The cream formulation was developed, and the quality control parameters were examined. Furthermore, the produced formulation's 5α-reductase inhibitory activity was tested using finasteride as a positive control. H. rosa sinensis, E. alba, and S. nigrum extracts, which comprise 0.35% oleanolic acid, 4.65% β-sitosterol, and 31.18% linoleic acid, were used in the formulation. HPTLC data revealed that each 10 gm of cream formulation contains 16.68 ± 0.21 mg of linoleic acid, 3.61 ± 0.18 mg of β-sitosterol and 0.380 ± 0.11 mg oleanolic acid. In-vitro results showed a good 5α-reductase inhibitory potential. The IC50 value of the developed formulation was 85.254 ± 0.888 μg/ml, whereas finasteride (positive control) was 223.039 ± 1.367 ng/ml. Thus, the herbal hair cream composition benefits alopecia therapy by inhibiting the 5α- reductase enzyme. In addition, the formulation might be a potential option for further research into its antiandrogenic properties.

Chitosan and Aloe Vera decorated nanoparticulate system loaded with Minoxidil as a suggested topical formulation for alopecia therapy

Minoxidil (Mxd) is a common medication used for hair regrowth in patients exhibiting different types of alopecia, especially androgenetic alopecia (AGA), but it has some negative aspects such as causing adverse effects and having limited permeation through the outer skin layers. In this study, minoxidil was encapsulated into niosomes and then loaded into chitosan nanoparticles and Aloe vera for creating a nanocomposite (Cs@Alo/Nio-Mxd), which will be used as a topical formulation to overcome these difficulties. The various prepared samples were physico-chemically characterised by their loading efficiency, TEM, SEM, zeta potential, FTIR and in vitro release profiles. The hair growth potential of the prepared formulations was evaluated by an in vivo study using rats with induced alopecia. Thirty-six rats with induced alopecia were randomised into six groups of six rats each. Group 1 (Negative control): rats served as normal and were treated with normal saline, Group 2: rats were treated with topical application of empty nanocomposites. Group 3 (Positive control): rats were treated with topical application of 5% Mxd, Group 4: rats were treated with topical application of (Cs-Mxd NPs), Group 5: rats were treated with topical application of (Cs@Alo-Mxd NPs). Group 6: rats were treated with topical application of (Cs@Alo/Nio-Mxd) nanocomposite. All formulations were applied once daily for 21 days. The treated skin was observed, photographed, and its histological features were examined. Results specified that Cs@Alo/Nio-Mxd nanocomposite could be preferentially deposited into the hair follicles, causing a significant increase (p < 0.05) in skin thickness, total hair follicle number per field, hair follicle diameter, hypodermis hair follicle number and anagen induction percentage.

A lipid-polymer hybrid nanoparticle (LPN)-loaded dissolving microneedle patch for promoting hair regrowth by transdermal miR-218 delivery.

Alopecia is the most common multifactorial hair loss disorder, affecting almost 50% of the population and even having a serious psychological impact on the patients. miR-218 has therapeutic potential for alopecia since it can activate the Wnt/β-catenin channel by down-regulating SFRP2, which is a key channel in hair follicle cycle transformation for hair regrowth. Although miR-218 has the potential to treat this disease, several barrier properties of the skin challenge miRNA's delivery to the target location, such as passing through the corneum and resistant enzymatic degradation. To address these challenges, we evaluated a device that combined the use of hyaluronic acid (HA)-based dissolving microneedle (MN) to enhance corneum permeability with the lipid polymer hybrid nanoparticles (LPNs) as a miRNA delivery carrier to protect miR-218 from degradation. The MN patches could promote LPNs/miR-218 diffusing in the dermis region, and significantly increase the bioavailability of miR-218. Furthermore, in the shaved mouse model, the MN patches showed higher efficacy in promoting hair growth than the topical smear treatment, while avoiding the safety concern. This work established a novel and effective combination device with MN and LPNs that can be used for localized transdermal miRNA delivery to promote hair regrowth.

Effects of Baicalin on Alopecia and the Associated Mechanism.

The aim of the present study was to explore the potential pharmacological mechanism of baicalin by combining network pharmacology prediction and the experimental verification of alopecia. Networks of baicalin-associated targets and alopecia-related genes were constructed using the STRING database. Potential targets and pathways associated with the therapeutic efficacy of baicalin were identified via enrichment analysis using Cytoscape and the database for annotation, visualization and integrated discovery (Metascape). The back hair of C57BL/6J mice was removed with depilatory cream to verify the therapeutic effect of baicalin. Human hair dermal papilla cells (HHDPCs) were used to explore the mechanism of action of baicalin. Network pharmacology analysis revealed that the potential targets of baicalin mainly include protein serine/threonine kinase, Src protein, epidermal growth factor receptor, and insulin-like growth factor 1 (IGF1), which were indicated to mediate neutrophil degranulation and regulation of cell-cell adhesion, vesicle lumen, cytoplasmic vesicle, membrane raft, and endopeptidase activity. Multiple pathways were identified, such as proteoglycans in cancer, PI3K/AKT, and forkhead box O signaling pathways. Following baicalin treatment for the experimental mice, the coverage, length, and weight of the hair increased in a baicalin dose-dependent manner. Moreover, the histological evaluation showed that the number of hair follicles increased after baicalin treatment and melanin formation were pronounced. In addition, baicalin induced an increase in the phosphorylated p-AKT, p-glycogen synthase kinase-3β, p-PI3K, TGF-β1, and vascular endothelial growth factor levels. Furthermore, the activation levels of key protein p-AKT were increased. Baicalin induced the proliferation of HHDPCs in vitro and significantly upregulated p-AKT, IGF1, and alkaline phosphatase. In conclusion, the present study revealed that the pharmacological mechanisms of baicalin in alopecia therapy were associated with the proliferation of DPCs, the activation of the AKT pathway, and the transmission of downstream signals, indicating that baicalin is a potential drug candidate for the clinical treatment of hair loss.

Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study.

Alopecia is a treatable disorder that usually occurs due to high levels of 5-alpha dihydrotestosterone in hair follicles. To enhance the storage capacity of hair follicles and alleviate the inherent characteristics of dutasteride, 5-alphareductaseinhibitor, a prolonged-release nanocarrier was synthesised, and its influence on rat abdomen's skin was investigated. Results showed the lower ratio of S/Co (higher ethanol concentration) increased the hydrodynamic nanocarriers' particle size due to thermodynamic disturbance and Ostwald ripening. In contrast, an increase in surfactant through a decrease in interfacial tension resulted in smaller nanocarriers of 32.4nm. Moreover, an increase in viscosity had an inverse correlation with the nanoemulsions' particle size. Nanocarriers containing ethanol showed less entrapment efficacy, perhaps due to the rapid dissolution of dutasteride into ethanol during nanoemulsification, while, based on Stokes' equation, the addition of ethanol resulted in smaller particle size and stability of the system. Skin permeation analysis using Franz diffusion cells showed nanocarriers could pass through the skin and release dutasteride for 6days. In conclusion, the optimum concentration of ingredients is decisive in guaranteeing the ideal particle size, stability, and skin permeation of nanocarriers. The Present dutasteride nanocarrier would promise a prolonged and sustained-release drug delivery system for Alopecia therapy.

Baricitinib: First Systemic Oral Drug for Alopecia Therapy

Baricitinib, a Janus kinase inhibitor, was originally approved as anti-rheumatic drug in 2017. In 2020, it was approved for the treatment of COVID-19 in selected hospitalized adults. Baricitinib received priority review designation for treatment of adult patients with severe alopecia areata and got USFDA approval on June 23, 2022 based on the results of 02 phase III trial: BRAVE-AA1 and BRAVE-AA2. In this review, we aim to summarize the different pharmacokinetic and pharmacodynamics aspects including drug interactions, adverse effects/black box warnings and their clinical relevance. We reiterate that oral JAK inhibitors are expensive, may carry significant risks, and are not yet recommended for routine treatment of alopecia areata. There is ongoing research on other topical and oral JAK inhibitors (tofacitinib and ruxolitinib), giving hope that better treatments for alopecia areata will become available in future.

A multifunctional cholesterol-free liposomal platform based on protopanaxadiol for alopecia therapy

A multifunctional cholesterol-free liposomal platform based on protopanaxadiol for alopecia therapy

Exosome therapy in hair regeneration: A literature review of the evidence, challenges, and future opportunities.

Alopecia is a common chief complaintand is challenging to treat. As such, regenerative treatments to promote hair growth are an emergingarea of research. Exosomes, which are extracellular vesicles involved in cell communication, homeostasis, differentiation, and organogenesis, have been shown to play a central role in hair morphogenesis and regeneration with potential for use as alopecia treatment. This review summarizes and assesses the body of literature surrounding exosomes as regenerative therapeutics for alopecia and identifies areas for improvement in future research. A review was conducted using a comprehensive list of keywords including "exosome," "alopecia," and "hair loss" on PubMed, EMBASE, and Google Scholar databases published from inception to February 2022. Reference lists of identified articles were included. 47studies were included. Clinical trial databases were searched using the term "exosome"; however, no trials relevant to hair growth were identified. Our updated and comprehensive review details the history of exosome use in medicine, postulated underlying mechanisms in treating hair loss, and current clinical studies. Preclinical studies demonstrate clear benefits of exosome therapeutics in regenerative medicine and for hair loss treatment. Clinical trials demonstrate safety of exosome use in medicine, but data showing efficacy and safety of exosome therapy for alopecia are lacking. We identified several gaps in knowledge required for effective clinical translation including safety, exosome source, and optimal treatment delivery mechanism and dosage. Exosomes are on the horizon as an exciting therapeutic for the treatment of alopecia. Further studies and clinical trials are required.

Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia

Alopecia is a condition associated with different etiologies, ranging from hormonal changes to chemotherapy, that affects over 80 million people in the USA. Nevertheless, there are currently few FDA-approved drugs for topical treatment, and existing formulations still present skin irritation issues, compromising treatment adherence. This work aimed to develop a safe formulation based on nanostructured lipid carriers (NLC) that entrap an association of minoxidil and latanoprost and target drug delivery to the hair follicles. To do so, thermal techniques combined with FTIR were used to assess the chemical compatibility of the proposed drug association. Then, NLC with 393.5 ± 36.0 nm (PdI < 0.4) and +22.5 ± 0.2 mV zeta potential were produced and shown to entrap 86.9% of minoxidil and 99.9% of latanoprost efficiently. In vitro, the free drug combination was indicated to exert positive effects over human primary epidermal keratinocytes, supporting cell proliferation, migration and inducing the mRNA expression of MKI67 proliferation marker and VEGF – a possible effector for minoxidil-mediated hair growth. Interestingly, such a favorable drug combination profile was optimized when delivered using our NLC. Furthermore, according to the HET-CAM and reconstructed human epidermis assays, the nanoformulation was well tolerated. Finally, drug penetration was evaluated in vitro using porcine skin. Such experiments indicated that the NLC could be deposited preferentially into the hair follicles, causing a considerable increase in the penetration of the two drugs in such structures, compared to the control (composed of the free compounds) and generating a target-effect of approximately 50% for both drugs. In summary, present results suggest that hair follicle-targeted delivery of the minoxidil and latanoprost combination is a promising alternative to treat alopecia.

Comparative efficacy of transdermal forms for alopecia therapy

Introduction. Alopecia is a polyetiological disorder characterized by hair loss and reducing their number per unit area. Baldness causes psychological and social discomfort to patients, in connection with what an important task is to develop formulations that are more effective than the reference agents.Aim. Investigate the possibility of applying the original substance Y in several dosage forms for the treatment of alopecia in comparison with reference drugs: minoxidil and burdock oil.Materials and methods. The research subject was the original substance Y, for which several dosage forms were made: gel, alcohol and oil compositions. The study on the effectiveness and safety of the developed formulations was carried out on 9 groups of male C57BL/6 mice. Depilation with further assessment of the percentage of hair follicles in the growth and resting phases was tested as a pre-clinical model of alopecia. In the study of the mechanism of action of substance Y, chemiluminescent assay was performed compared with natural antioxidant quercetin in the system luminol – 2,2'-azo-bis(2-amidinopropane)dihydrochloride, in potassium-phosphate buffer medium (pH = 7.4). Statistical processing of the results was carried out using two-way ANOVA using GraphPad Prism 8.0.2, USA software at the level of statistical significance of differences p &lt; 0.05 and p &lt; 0.005.Results and discussion. Based on the results of histological analysis and visual changes, it was found that the effectiveness of the topical forms of substance Y decreases in the following order: gel, alcohol form, oil composition. The use of a combination of the gel base with the test substance Y resulted to the appearance of a larger number of hair follicles in the growth phase than when using the reference preparation – 2 % minoxidil solution (the differences are statistically significant). Chemiluminescent assessment of antioxidant activity showed the lack of antioxidant effect in substance Y.Conclusion. The study combines two pharmaceutical profiles: technological and pharmacological. In the course of the experiments, the prospects of the gel form of the original substance Y for topical therapy of alopecia were shown. In the near future, it is planned to study the mechanism of action of substance Y, as well as registration of patent protection for a new drug.

Determination of protonation state in molecular salt of minoxidil and 2,4-dihydroxybenzoic acid through a combined experimental and theoretical study: influence of proton transfer on biological activities

Topical minoxidil (MXD) is frequently used as therapy for alopecia. In this study, a new MXD molecular salt formed by MXD and the 2,4-dihydroxybenzoic acid (24HA) were prepared and characterized. The nature of the MXD/24HA salt was studied using infrared spectrometry, single-crystal and powder X-ray diffraction, X-ray photoelectron spectroscopy, Hirshfeld surface analysis, and configuration interaction calculations. The theoretical results and the experimental data show that the proton transfer accompanies the formation of the MXD/24HA salt. The resulted MXD/24HA salt crystallizes in themonoclinic space group P21/c. The in vivo assessment with the hair growth model in mice reveals that the MXD/24HA salt is superior to the raw MXD. Thus, the MXD/24HA salt can potentially be a candidate drug for hair loss. The combination of theory and experiment enables an innovative methodology to understand the differences in structure and properties of pharmaceutical salts.

Follicular-targeted delivery of spironolactone provided by polymeric nanoparticles

This study proposes developing a topical formulation based on poly-ε-caprolactone (PCL) or methacrylic acid/methyl methacrylate copolymer (EL100) nanoparticles to enable a safer and more effective therapy of alopecia and acne with spironolactone. The effect of the size of the nanoparticle on follicular-targeted drug delivery is also verified. Compatibility studies based on thermal analyses and complementary techniques showed a small interaction of the drug with excipients, which may not compromise the drug stability. PCL nanoparticles of 180.0 ± 1.6 and 126.8 ± 1.0 nm, and EL100 nanoparticles of 102.7 ± 7.1 nm were then prepared. All nanoparticles entrapped more than 75 % of spironolactone, were physically stable, and stabilized the drug for at least 90 days. They were also non-irritant according to HET-CAM tests. Drug release from the nanoparticles was reduced in aqueous buffer media but fast when in contact with oil. Finally, in vitro skin penetration experiments revealed the largest nanoparticles (of 180 nm) targeted drug delivery to the hair follicles 5-fold (p < 0.05) more than the control solution, 2.1-fold (p < 0.05) more than nanoparticles produced with the same polymer (PCL) but with smaller size (123 nm), and 4.9-fold (p < 0.05) more than the 102-nm E100 nanoparticles. In conclusion, follicular targeting can be adjusted according to nanoparticle size, and this work succeeded in obtaining polymeric nanoparticles adequate to enable topical treatment of acne and alopecia with spironolactone.

Nanostructured Lipid Carriers Loaded with an Association of Minoxidil and Latanoprost for Targeted Topical Therapy of Alopecia

Nanostructured Lipid Carriers Loaded with an Association of Minoxidil and Latanoprost for Targeted Topical Therapy of Alopecia

The Utility of Platelet-Rich Plasma for the Treatment of Alopecia.

Importance: Platelet-rich plasma (PRP) is a novel therapy for alopecia. Although the use of PRP remains under investigation, medical practitioners administer PRP for hair regrowth without quantitative evidence of clinical results. Objective: Systematically review literature regarding PRP for alopecia. Evidence Review: PRISMA guidelines were utilized to search the PubMed database in May 2019 with search terms "platelet rich plasma" and "hair", "hair loss", or "alopecia". Manuscripts were included if they were written in English and described PRP treatment in human subjects with alopecia. Findings: Sixty-one articles discussed the use of PRP as monotherapy, or in combination with other medical modalities, for the treatment of androgenetic alopecia (AGA), alopecia areata (AA), and cicatricial alopecia, ranging from level Ib to IV evidence. PRP results in significant increase in hair density and hair shaft width in AGA patients, with high rates of patient satisfaction and minimal adverse events. Data heterogeneity and limited number of well-designed, large-scale clinical trials were limitations of this review. Conclusions and Relevance: Preliminary results regarding the use of PRP for AGA, AA, and cicatricial alopecias are promising. Physicians should be aware that current studies often report qualitative, rather than quantitative, clinical outcomes and should counsel patients regarding PRP treatment efficacy accordingly. J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.5192.